MedTrace Logo

Retinal OCT Changes and Biomarkers in Drug-Resistant Epilepsy

NCT07716930 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2026-07-21

No results posted yet for this study

Summary

This prospective, longitudinal observational study investigates whether epilepsy involves a progressive neurodegenerative process. Retinal structural and microvascular changes assessed by optical coherence tomography (OCT) and optical coherence (OCTA) will be analyzed alongside inflammatory biomarkers (sCD14, sCD163, CCL2, IL-1β). The study aims to explore their association with epilepsy pathophysiology, clinical phenotype, prognosis, and drug-resistant epilepsy (DRE). Among participants with epilepsy, seizure severity and antiseizure medication-related adverse-effect burden will also be assessed longitudinally using the National Hospital Seizure Severity Scale (NHS3) and the Turkish version of Liverpool Adverse Events Profile (LAEP-TR).

Conditions

  • Epilepsy (Treatment Refractory)
  • Epilepsy

Sponsors & Collaborators

  • Haydarpasa Numune Training and Research Hospital Department of Neurology

    collaborator UNKNOWN

  • Haydarpasa Numune Training and Research Hospital Department of Ophthalmology

    collaborator UNKNOWN

  • Istanbul University Aziz Sancar Institute of Experimental Medicine

    collaborator UNKNOWN

  • Health Institutes of Türkiye

    collaborator UNKNOWN

  • Kemal Tutkavul

    lead OTHER

Principal Investigators

  • KEMAL TUTKAVUL, Professor · Saglik Bilimleri University Haydarpasa Numune Education and Research Hospital Neurology Clinic

  • NUR D BASPINAR, MD · Saglik Bilimleri University Haydarpasa Numune Education and Research Hospital Neurology Clinic

  • ECE TURAN VARDAR, Professor · Saglik Bilimleri University Haydarpasa Numune Education and Research Hospital Ophthalmology Clinic

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2028-01-31
Completion
2028-04-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07716930 on ClinicalTrials.gov